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Purpose: Renal cell carcinoma is a heterogeneous kidney cancer, and over 403,000 cases were reported worldwide in 2018. Current 
methods for studying renal cell carcinoma are limited to two-dimensional (2D) culture of primary cell lines and patient-derived 
xenograft models. Numerous studies have suggested that 2D culture poorly represents the diversity, heterogeneity, and drug-
resistance of primary tumors. The time and cost associated with patient-derived xenograft models poses a realistic barrier to their 
clinical utility. As a biomimetic model, patient-derived three-dimensional (3D) organoid culture can overcome these disadvantages 
and bridge the gap between in vitro  cell culture and in vivo patient-derived xenograft models. Here, we establish a patient-derived 
3D organoid culture system for clear cell renal cell carcinoma and demonstrate the biomimetic characteristics of our model with 
respect to both primary kidney cancer and conventional 2D culture.
Materials and Methods: Normal renal tissues and tumor tissues were collected from patients with clear cell renal cell carcinoma. 
The dissociated cells were cultured as conventional 2D culture and 3D organoid culture. The biomimetic characteristic of the two 
cultures were compared.
Results: Compared with 2D culture, the 3D organoid cultures retained the characteristic lipid-rich, clear cell morphology of clear 
cell renal cell carcinoma. Carbonic anhydrase 9 and vimentin were validated as biomarkers of renal cell carcinoma. Expression of 
the two validated biomarkers was more enhanced in 3D organoid culture. 
Conclusions: Patient-derived 3D organoid culture retains the characteristics of renal cell carcinoma with respect to morphology 
and biomarker expression.
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INTRODUCTION
The most common type of kidney cancer is renal cell 
carcinoma, which arises from the epithelial cell lining of the 
proximal convoluted tubule [1]. Despite progress in systemic 
therapy of advanced renal cell carcinoma, the progression-
free survival rate remains less than 1 year [2]. To overcome 
this poor prognosis, the therapeutic paradigm of advanced 
renal cell carcinoma has begun to shift in favor of preci-
sion medicine. Precision medicine is an approach to an indi-
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vidualized treatment model that seeks to identify effective 
therapy for every patient [3]. In this model, diagnostic test-
ing is used to facilitate the selection of appropriate and op-
timal therapies based on an individual’s genetic, molecular, 
or cellular signature. Owing to the intrinsic heterogeneity of 
renal cell carcinoma, precision medicine offers an attractive 
alternative to conventional therapies. Thus, development of 
a patient-derived in vitro model is essential for the realiza-
tion of precision medicine in this diverse carcinoma.
Cancer cell lines and patient-derived xenografts are the 
most frequently used models in cancer research and anti-
cancer drug screening for precision medicine [4]. Numerous 
studies have noted the limitations of two-dimensional (2D) 
culture of primary cell lines, especially in terms of their 
translation to human biology and treatment of tumors oc-
curring in patients [5,6]. Cell-cell and cell-matrix interactions 
control cell phenotypes and function in vivo, making it es-
sential to maintain these interactions in vitro to produce 
and retain cultured cell fidelity to normal phenotype and 
plasticity [7]. Patient-derived xenograft models address this 
concern but are plagued by their own limitations. These 
limitations include instability of engraft efficiencies and 
inaccurate reflections of the tumor microenvironment and 
immune system compared with those of the patient [8]. In 
addition, patient-derived xenograft models are costly and 
time-consuming, posing the most significant nonscientific 
barrier to the implementation of  precision medicine for 
each carcinoma type [8]. Recently, cancer organoid cultures 
have been developed to establish in vitro growth of patient-
derived samples at higher efficiency, and these systems are 
a promising alternative for use in fundamental cancer biol-
ogy research as well as in large-scale drug screening [9,10].
Organoids are a miniature model of three-dimensional 
(3D) epithelial structure and recapitulate the histology and 
differentiation of the original organ [11-13]. These systems 
are derived from a small number of cells from primary tis-
sues, embryonic stem cells, or induced pluripotent stem cells. 
Importantly, organoids retain the functionality of  their 
tissue of origin and are capable of self-renewal and self-
organization [14,15]. These characteristics of 3D organoid cul-
ture systems bridge the gap between traditional in vitro cell 
culture and in vivo patient-derived xenograft models [15]. In 
the present study, we establish a method for “patient-derived 
3D organoid culture” from patients with advanced renal cell 
carcinoma. This study reveals the correlation between pri-
mary cancer tissue and patient-derived 3D organoid culture 
in this cancer type and provides the groundwork for future 
investigation of precision medicine for renal cell carcinoma.
MATERIALS AND METHODS
1. Human tissue
Normal renal tissues and renal cell carcinoma tissues 
were collected from patients who provided informed con-
sent as stipulated by the Institutional Review Board (IRB) 
at Yonsei University (College of Medicine), and the study 
protocol was approved by the ethics committee (approval 
number: 4-2015-0104). Tissue samples were acquired from 13 
patients who were enrolled in the study. The clinical data of 
the included patients are provided in Supplementary Table 1. 
Normal tissues were sampled at a distance from the tumor.
2. Organoid culture
For tissue dissociation, dissected human kidney tissue 
was minced with a blade to yield 1×1-mm pieces. Kidney tis-
sues were incubated in 5 mL of Dulbecco’s Modified Eagle's 
Medium (DMEM)/F12 (Gibco, Grand Island, NY, USA) 
supplemented with 1% fetal bovine serum (FBS), 3 mg/mL 
collagenase type II (Sigma-Aldrich, St. Louis, MO, USA), and 
1× antibiotic antimycotic solution (Sigma-Aldrich) at 37ºC for 
2 hours to digest tissue. After incubation, dissociated tissue 
was triturated vigorously by pipetting for 1 minute and then 
passed through a 70-μm cell strainer (Corning, New York, 
NY, USA). The cell pellet was centrifuged at ~200×g for 2 
minutes and then gently washed with phosphate-buffered 
saline (PBS) twice. The cell pellets were resuspended in 1 to 
2 mL of Matrigel (approximately 1×103 cells/μL of Matrigel; 
Corning) on ice and loaded in a 6-well plate. After polymer-
ization of Matrigel, cells were incubated in YRC media, the 
organoid culture medium for kidney consisting serum-free 
keratinocyte medium (Gibco) supplemented with 0.01 mg/
mL recombinant human insulin, 55 μg/mL human transfer-
rin (substantially iron-free, Sigma-Aldrich), 5 ng/mL sodium 
selenite (ITS supplement, Sigma-Aldrich), 500 nM hydrocor-
tisone (Sigma-Aldrich), 100 ng/mL human recombinant Nog-
gin (PeproTech, Rocky Hill, NJ, USA), 10 nM leucine (Sigma-
Aldrich), 5 μM Y-27632 (Enzo LifeSciences, Farmingdale, 
NY, USA), and 5% FBS. For serial passaging experiments, 
organoids were passaged at a 1:4 dilution every 1 to 2 weeks 
with 0.25% trypsin for 5 minutes at 37ºC, followed by me-
chanical dissociation to nearly single cell suspensions. As a 
control group, a normal cell culture container was used, and 
the control group cells were serially passaged four times.
3. H&E staining
To characterize the 3D organoid culture and cell char-
acteristics, a portion of the Matrigel under the 3D organoid 
culture was removed and re-solidified in 1.2% agarose in 
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DMEM. After fixation in 10% formalin for 24 hours, samples 
were embedded in paraffin. Paraffin blocks were sectioned 
and adhered to slides. The slides were immersed in Xylene 
solution and then rehydrated by immersion in sequential 
ethanol dilutions. After soaking in hematoxylin solution for 
8 minutes, slides were rinsed with running water. Finally, 
slides were incubated in eosin solution for 2 minutes and 
dehydrated using sequential ethanol and Xylene solution. 
DePeX (Serva, Heidelberg, Germany) solution was used for 
coverslip mounting, and slides were observed with an optical 
microscope.
4. Cell proliferation assay (CCK-8 assay) 
Cells were loaded in triplicate in 48-well culture plates 
with Matrigel (12,000 cells/25 μL of each Matrigel dome). 
Cells were incubated for 72 hours in McCoy media and 
YRC organoid media, respectively. The cell proliferation 
was detected by use of cell counting kit-8 (CCK-8; Dojindo 
Laboratories, Kumamoto, Japan). To each well and plates 
2-(2-Methoxy-4-nitrophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfo-
phenyl)-2H-tetrazolium, monosodium salt was added and 
were incubated for 1 hour. A water-soluble formazan prod-
uct in media was determined by using a Beckman Coulter 
microplate reader (Beckman Coulter, Miami, FL, USA) at 
450 nm.
5. Immunofluorescence assay
The expression levels of  carbonic anhydrase 9 (CA9), 
vimentin, and pan-keratin were compared by using immu-
nofluorescence. Cancer cells and normal cells from patients 
were cultured in 8-well chamber slides (Labtech, East Sus-
sex, UK). Each cell was seeded for 5 hours after trypsin 
treatment and removal of Matrigel. Cells were fixed with 
4% paraformaldehyde solution for 10 minutes and then 
washed with PBS. Cells were then permeated in 0.5% Triton 
X-100 in PBS for 5 minutes, blocked in 5% bovine serum 
albumin (BSA) in PBS for 20 minutes, and incubated with 
diluted primary antibodies to CA9 (1:100; Novus Biologicals, 
Littleton, CO, USA), vimentin, and pan-keratin (Cell Signal-
ing Technology, Danvers, MA, USA) in 5% BSA at 4ºC for 
16 hours. Cells were washed with PBS and then incubated 
with secondary antibodies tagged with Alexa Fluor 488 or 
594 (Molecular Probes, Eugene, OR, USA) at 25ºC for 1 hour 
(1:200). Images were acquired by laser scanning confocal 
microscopy (laser scanning microscope [LSM] Meta 700; Carl 
Zeiss, Oberkochen, Germany) and analyzed with LSM Image 
Browser software.
6. Immunohistochemical staining
Tissues from patients were embedded in paraffin, and 
2-μm sections were prepared for immunohistochemical stain-
ing. After paraffin removal, the slides were pretreated in 0.01 
M citric acid buffer (pH 6.0) for 10 minutes. After blocking 
with peroxidase blocking solution (Dako, Carpinteria, CA, 
USA), slides were incubated with primary anti-CA9, anti-
vimentin, and anti-pan-keratin antibodies as described for 
immunofluorescence in 5% BSA (1:100) at 4ºC overnight. Af-
ter washing in Tris-HCl buffer, the specific immunoreaction 
was detected using a secondary horseradish peroxidase–con-
jugated goat anti-rabbit antibody (1:200; Dako). After wash-
ing in Tris-HCl buffer, 3-3-diaminbenzidine tetrahydrochlo-
ride (DAB+; Dako) was used for visualization. Sections were 
counter stained with hematoxylin, dehydrated, mounted 
with DePeX (Serva), and examined with a microscope.
7. Quantitative real-time polymerase chain reac-
tion analysis
Total RNA was extracted from organoids using TRIzol 
(Invitrogen [thermo fisher], Grand Island, NY, USA) and 
purified by use of RNeasy Mini Kits (Qiagen Korea, Seoul, 
Korea) in accordance with the manufacturer’s protocol. For 
cDNA synthesis, 500 ng of RNA from each sample was re-
verse transcribed using the Superscript First Strand Synthe-
sis system (Invitrogen). Quantitative real-time polymerase 
chain reaction (RT-PCR) was performed using SYBR green 
master mix reagent (Qiagen Korea) on an Applied Biosystem 
Step One Plus system (Applied Biosystems, Foster City, CA, 
USA). The cDNA samples were analyzed in triplicate for all 
analyses. To obtain relative values, the ΔΔCT method was 
used, and values were normalized to glyceraldehyde-3-phos-
phate dehydrogenase (GAPDH) expression. Average values 
are shown. Primers were purchased from Qiagen Korea.
8. Western blot
Total protein extracts from organoids were prepared on 
ice using PRO-PREP protein extract solution (Intron, Seoul, 
Korea). Proteins from cell lysates were separated on a so-
dium dodecyl sulfate polyacrylamide gel and transferred to 
polyvinylidene fluoride membrane for 1 hour. Membranes 
were incubated at 4ºC overnight with anti-CA-9 and anti-
GAPDH primary antibodies (Abcam, Cambrige, UK) diluted 
1:1,000 with 5% BSA Tris-buffered saline-Tween 20 (TBS-T). 
After incubation, the membrane was washed with TBS-T, 
and then secondary antibodies (1:10,000; horseradish peroxi-
dase-conjugated anti-mouse immunoglobulin G [IgG] or anti-
rabbit IgG) were applied at room temperature for 1 hour. 
Labeled bands were detected by use of a West Pico chemilu-
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minescent kit (Thermo Scientific, Rockford, IL, USA).
9. Statistical analysis
Quantitative values were expressed as mean±standard 
error of the mean. Statistical differences were assessed using 
the Mann–Whitney U-test with IBM SPSS Statistics version 
23.0 (IBM Corp., Armonk, NY, USA). A p<0.05 was consid-
ered statistically significant.
RESULTS
1. Morphologic characteristics of patient-derived 
3D organoid culture of renal cell carcinoma
Hematoxylin and eosin (H&E)-stained samples of clear 
cell renal cell carcinoma showed the typical characteristics 
and morphology observed in the primary tissue (Fig. 1A). 
To evaluate whether 3D organoid culture retains the mor-
phological characteristics of the primary tissue, organoid 
samples were examined under light microscopy. We observed 
that 3D organoid culture cells clustered to form a diverse 
colony that exhibited patterns similar to those found in the 
primary tissue (Fig. 1B). The samples were then embedded 
in paraffin and stained with H&E (Fig. 1C). Lipid-rich, clear 
cell morphology was readily observed, consistent with the 
primary tissue. In comparison to 2D culture, which shows 
morphologic denaturation after several passages (Supple-
mentary Fig. 1), we observed that cell morphology in patient-
derived 3D organoid culture was maintained (Supplementary 
Fig. 2). Thus, the main characteristics of primary clear cell 
renal cell carcinoma tissue were well maintained in organoid 
culture.
2. Validation of biomarkers of renal cell carcinoma 
in 2D culture, 3D organoid culture, and primary 
tissue
CA9, keratin, and vimentin were previously identified 
as biomarkers of renal cancer cells. To evaluate our 3D or-
ganoid culture system, we compared the expression patterns 
of these biomarkers between normal and cancer cells in 2D 
and 3D organoid culture as well as in primary tissue. Immu-
nofluorescence analysis of 2D cultured renal cells revealed 
that CA9 and vimentin were more strongly expressed in 
cancer cells, whereas keratin was more strongly expressed 
in normal cells (Fig. 2A). The expression of CA9 and keratin 
was enhanced more in 3D organoid culture than in nor-
mal cells (Fig. 2B). Consistent with our in vitro results, the 
expression of CA9 and vimentin in primary cancer tissue 
was stronger than in primary normal kidney tissue (Fig. 
2C). Furthermore, the scores of CA9 and vimentin using im-
munohistochemical staining were highly positive in tissue 
samples from 5 patients with renal cell carcinoma (Fig. 2D). 
To quantify the increased expression of CA9 and vimentin 
in cancer cells, we performed RT-PCR analysis of normal 
and cancer tissues. The expression of both CA9 and vimen-
tin was higher in cancer cells than in normal cells (Fig. 2E).
3. Increased expression of CA9 and vimentin in 
patient-derived 3D organoid culture of renal 
cell carcinoma
After establishing the validity of CA9, keratin, and vi-
mentin as biomarkers in this model, we examined the dif-
ferences in expression between 2D culture and 3D organoid 
culture. We found that the expression of CA9 and vimentin 
was significantly enhanced in 3D organoid culture compared 
with 2D culture. Immunofluorescence analysis showed that 
CA9 and vimentin were more strongly expressed in 3D 
A B C
Tissue-H&E 3D-Brightfield 3D-H&E
Fig. 1. Morphologic characteristics in patient-derived three-dimensional (3D) organoid culture of renal cell carcinoma. (A) Clear cell renal cell 
carcinoma morphology in primary tissue by hematoxylin and eosin (H&E) stain. (B) 3D organoid culture under light microscopy shows diverse 
colonies. (C) Paraffin blocked samples of 3D organoid culture show morphology similar to that of clear cell renal cell carcinoma in primary tissue. 
All scale bars, 20 μm.
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organoid culture (passage 4) than in 2D culture (Fig. 3A). 
Additionally, the relative mean intensity score of CA9 and 
vimentin, as assessed by RT-PCR, was significantly higher 
in 3D organoid culture than in 2D culture (p<0.05; Fig. 
3B). Furthermore, the fold upregulation in CA9 expression 
evaluated by RT-PCR indicated that the expression of CA9 
was considerably increased in 3D organoid culture (Fig. 3C). 
The increased expression of CA9 in 3D organoid culture was 
confirmed by Western blot (Fig. 3D).
DISCUSSION
The advent of 3D organoid culture systems has advanced 
research on cancer, disease progression, metastasis, and 
treatment in many tissues, including the prostate, colorectal 
tissue, and liver. Prostate cancer is a leading cause of death 
among men in the United States and Western Europe [16]. 
A novel model of 3D organoid culture for advanced pros-
tate cancer was reported in 2014 [17]. It was confirmed that 
this model reflects the nature of the original prostate can-
cer tissue. In addition to the models of organoid culture in 
colorectal cancer, models of hepatocellular carcinoma have 
been reported, which showed that the 3D organoid culture 
model preserves the properties of the original tissues well 
compared with the primary cancer tissue [18,19]. Owing to 
the poor prognosis of patients with advanced renal cell car-
cinoma, development of a patient-specific precision model, 
such as 3D organoid culture, is imperative. However, there 
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Fig. 2. Biomarker comparison in two-dimensional (2D) culture, patient-derived three-dimensional (3D) organoid culture, and primary tissue. (A) 
Immunofluorescence analysis of carbonic anhydrase 9 (CA9) (green), keratin (red), vimentin (green), and 4',6-diamidino-2-phenylindole (DAPI) 
(blue) expression in 2D cultured cancer and normal cells. Scale bars, 10 μm. (B) CA9 and keratin immunofluorescence in 3D organoid culture of 
cancer and normal cells. Scale bars, 10 μm. (C) Immunohistochemistry (IHC) staining of CA9 and vimentin in primary tissue from normal and renal 
cancer patients. (D) IHC scores of renal cancer tissue in 5 patients. (E) Real-time polymerase chain reaction fold induction of CA9 and vimentin in 
primary tissue of renal cancer patients relative to normal tissue.
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has been no previous report of development and validation 
of patient-derived 3D organoid culture.
In this study, we used our previous experience with a 
kidney tubular organoid model [20] to establish a technique 
for 3D organoid culture of advanced renal cell carcinoma to 
better represent the characteristics of the original patient-
derived cancer cell. The gross and microscopic appearance of 
renal cell carcinoma is highly variable and poses a consider-
able challenge for culture models. With respect to the micro-
scopic context, there are four major histologic subtypes of re-
nal cell cancer: clear cell (conventional renal cell carcinoma, 
75%), papillary (15%), chromophobe (5%), and collecting duct 
(2%) [21]. We focused on the clear cell subtype, as this type 
is the most commonly observed renal cell carcinoma. Our 
patient-derived 3D organoid culture was comparable to the 
histology observed in clear cell renal cell carcinoma (Fig. 1). 
We showed that the diverse clustering of 3D organoid cul-
ture exhibits patterns that resemble those of the original cell 
colony. Furthermore, we observed that the main characteris-
tics of cell morphology, including a lipid-rich, clear cytoplasm 
and diverse colony formation, found in the primary tissue of 
clear cell renal cell carcinoma were well maintained in 3D 
organoid culture. Thus, patient-derived 3D organoid culture 
offers a potential biomimetic model of advanced renal cell 
carcinoma tissue.
CA9, keratin, and vimentin are well-known biomarkers 
in hypoxia and cancer metabolism, especially in renal cancer 
cells [22,23]. CA9 and vimentin are known to be upregulated 
in cancer cells, whereas keratin expression is reduced. We 
had investigated our patient-derived 3D organoid culture 
system using these well-known cancer biomarkers. We found 
that both 2D culture and patient-derived 3D organoid cul-
Fig. 3. Patient-derived three-dimensional (3D) organoid culture of renal cancer cells exhibits increased expression of carbonic anhydrase 9 (CA9) 
and vimentin. (A) Expression of CA9 and vimentin in 3D organoid culture (passage 4) and two-dimensional (2D) culture by an immunofluo-
rescence assay. Scale bars, 20 μm. (B) Real-time polymerase chain reaction (RT-PCR) relative mean intensity scores of CA9 and vimentin in 3D 
organoid culture compared to 2D culture (p<0.05). Error bar represents standard error of mean. (C) RT-PCR fold induction of CA9 and vimentin in 
3D culture relative to 2D culture. (D) Western blot of CA9 in 3D organoid culture and 2D culture. GAPDH, glyceraldehyde-3-phosphate dehydroge-
nase.
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ture of normal renal and renal cell carcinoma cells exhibited 
the expected patterns of expression of CA9, keratin, and vi-
mentin. The increased expression of CA9 and vimentin and 
the concomitant decreased expression of keratin in cancer 
cells was maintained in our patient-derived organoid culture 
model. We further characterized the expression of these bio-
markers in normal kidney tissue and renal cell carcinoma 
tissue and found that CA9 and vimentin were indeed ex-
pressed in cancer tissues as expected (Fig. 2C–E). Important-
ly, using immunofluorescence, RT-PCR, and Western blot-
ting, we found that the expression of CA9 and vimentin was 
enhanced in patient-derived 3D organoid culture compared 
with 2D culture (Fig. 3). It is suggested that patient-derived 
3D organoid culture is superior to 2D culture in terms of 
preserving the biomarker expression of the original cancer 
cells. Thus, our patient-derived 3D organoid culture model of 
clear cell renal cell carcinoma is consistent with patient biol-
ogy, providing a robust model for additional study. 
We note that there were several limitations to this study. 
The included number of patients in our study was small, 
and most of the samples were from low-stage tumors with-
out any aggressive features, such as sarcomatoid change. We 
plan to continue to expand our study to include more sam-
ples from tumors with high-grade, aggressive phenotypes.
Despite the challenges to developing an organoid cul-
ture system for renal cell carcinoma, this patient-derived 
3D organoid culture model may provide a new system for 
the development of a patient-specific in vitro clinical model 
of advanced renal cell carcinoma. The improved biological 
relevance of patient-derived 3D organoid culture makes it a 
promising model for fundamental cancer biology research as 
well as for large-scale drug screening. Future studies using 
this model may ultimately lead to the realization of preci-
sion medicine for patients with renal cell carcinoma. In this 
model, diagnostic testing is often used to select appropriate 
and optimal therapies in the context of a patient’s genetic 
content or other molecular or cellular analysis. 
CONCLUSIONS
We successfully established successful patient-derived 
organoid culture methods for advanced renal cell carcinoma. 
Our model retains the characteristics of  advanced renal 
cell carcinoma with respect to morphology and biomarker 
expression. This patient-derived 3D organoid culture model 
may provide a new system for the development of patient-
specific in vitro clinical models of advanced renal cell carci-
noma.
CONFLICTS OF INTEREST
The authors have nothing to disclose.
ACKNOWLEDGMENTS
This study was supported by a National Research Foun-
dation grant (NRF-2018R1D1A1B07050131) funded by the 
Korean government (MEST).
AUTHORS’ CONTRIBUTIONS
Research conception and design: Woong Kyu Han. Data 
acquisition: Sook Young Kim. Statistical analysis: Joon Chae 
Na and Sook Young Kim. Data analysis and interpreta-
tion: Joon Chae Na. Drafting of the manuscript: Joon Chae 
Na and Jee-Hoon Kim. Critical revision of the manuscript: 
Woong Kyu Han. Obtaining funding: Woong Kyu Han. 
Administrative, technical, or material support: Young-Ran 
Gu, Dae-Young Jun, Hyung Ho Lee, Young Eun Yoon, and 
Kyung Hwa Choi. Supervision: Sung Joon Hong. Approval of 
the final manuscript: Woong Kyu Han.
SUPPLEMENTARY MATERIALS
Scan this QR code to see the supplementary materials, or 
visit https://www.icurology.org/src/sm/icurology-61-216-s001.pdf.
REFERENCES
1. Cairns P. Renal cell carcinoma. Cancer Biomark 2010;9:461-73.
2. Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-
cell carcinoma. N Engl J Med 2017;376:354-66.
3. Pauli C, Hopkins BD, Prandi D, Shaw R, Fedrizzi T, Sboner A, 
et al. Personalized in vitro and in vivo cancer models to guide 
precision medicine. Cancer Discov 2017;7:462-77.
4. Sachs N, Clevers H. Organoid cultures for the analysis of can-
cer phenotypes. Curr Opin Genet Dev 2014;24:68-73.
5. Ben-David U, Ha G, Tseng YY, Greenwald NF, Oh C, Shih J, et 
al. Patient-derived xenografts undergo mouse-specific tumor 
evolution. Nat Genet 2017;49:1567-75.
6. Mitra A, Mishra L, Li S. Technologies for deriving primary 
tumor cells for use in personalized cancer therapy. Trends Bio-
technol 2013;31:347-54.
223Investig Clin Urol 2020;61:216-223. www.icurology.org
Patient-derived organoid culture in RCC
7. Sharma R, Greenhough S, Medine CN, Hay DC. Three-dimen-
sional culture of human embryonic stem cell derived hepatic 
endoderm and its role in bioartificial liver construction. J 
Biomed Biotechnol 2010;2010:236147.
8. Malaney P, Nicosia SV, Davé V. One mouse, one patient para-
digm: new avatars of personalized cancer therapy. Cancer Lett 
2014;344:1-12.
9. Gao D, Chen Y. Organoid development in cancer genome dis-
covery. Curr Opin Genet Dev 2015;30:42-8.
10. Grassi L, Alfonsi R, Francescangeli F, Signore M, De Angelis 
ML, Addario A, et al. Organoids as a new model for improv-
ing regenerative medicine and cancer personalized therapy in 
renal diseases. Cell Death Dis 2019;10:201.
11. Artegiani B, Clevers H. Use and application of 3D-organoid 
technology. Hum Mol Genet 2018;27(R2):R99-107.
12. Miyoshi T, Hiratsuka K, Saiz EG, Morizane R. Kidney organ-
oids in translational medicine: disease modeling and regen-
erative medicine. Dev Dyn 2019 Mar 6 [Epub]. http://doi.
org/10.1002/dvdy.22. 
13. Morizane R, Bonventre JV. Kidney organoids: a translational 
journey. Trends Mol Med 2017;23:246-63.
14. Cantrell MA, Kuo CJ. Organoid modeling for cancer precision 
medicine. Genome Med 2015;7:32.
15. Fatehullah A, Tan SH, Barker N. Organoids as an in vitro 
model of human development and disease. Nat Cell Biol 
2016;18:246-54.
16. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N 
Engl J Med 2003;349:366-81.
17. Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, 
et al. Organoid cultures derived from patients with advanced 
prostate cancer. Cell 2014;159:176-87.
18. Takai A, Fako V, Dang H, Forgues M, Yu Z, Budhu A, et al. 
Three-dimensional organotypic culture models of human he-
patocellular carcinoma. Sci Rep 2016;6:21174.
19. van de Wetering M, Francies HE, Francis JM, Bounova G, Io-
rio F, Pronk A, et al. Prospective derivation of a living organoid 
biobank of colorectal cancer patients. Cell 2015;161:933-45.
20. Jun DY, Kim SY, Na JC, Lee HH, Kim J, Yoon YE, et al. Tu-
bular organotypic culture model of human kidney. PLoS One 
2018;13:e0206447.
21. Prasad SR, Humphrey PA, Catena JR, Narra VR, Srigley JR, 
Cortez AD, et al. Common and uncommon histologic subtypes 
of renal cell carcinoma: imaging spectrum with pathologic cor-
relation. Radiographics 2006;26:1795-806; discussion 806-10.
22. Ingels A, Hew M, Algaba F, de Boer OJ, van Moorselaar RJ, 
Horenblas S, et al. Vimentin over-expression and carbonic 
anhydrase IX under-expression are independent predictors 
of recurrence, specific and overall survival in non-metastatic 
clear-cell renal carcinoma: a validation study. World J Urol 
2017;35:81-7.
23. Pickering LM, Larkin J. Kidney cancer: carbonic anhydrase IX 
in resected clear cell RCC. Nat Rev Urol 2015;12:309-10.
